Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

The Mayo Clinic Cancer Center and Holden Comprehensive Cancer Center at the University of Iowa have received a five-year, $11.5 million grant renewal from the National Cancer Institute (NCI) to continue the Specialized Program of Research Excellence (SPORE) for lymphoma research.

25 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Researchers identify subgroups of B cells in MYC-positive germinal centers

Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce antibodies specific for the pathogen. However, it is known that the vast majority of lymphomas derive from the B cells at the germinal centers.

24 Sep 2012

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.

24 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.

21 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

21 Sep 2012

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

Investigators at Northwestern University Feinberg School of Medicine have identified two promising therapies to treat patients with acute megakaryocytic leukemia (AMKL), a rare form of leukemia where the number of cases is expected to increase with the aging population.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

No link between low-level electromagnetic field exposure from mobile phones and health risks

There is no scientific evidence that low-level electromagnetic field exposure from mobile phones and other transmitting devices causes adverse health effects, according to a report presented by a Norwegian Expert Committee. In addition, the Committee provides advice to authorities about risk management and regulatory practice.

18 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Objective response rate promising after crizotinib for NSCLC

More than half of the latest evaluated participants from the ongoing phase II PROFILE 1005 trial of crizotinib against ALK-positive advanced non-small-cell lung cancer, achieved an objective tumor response, report researchers.

14 Sep 2012

Crizotinib may be effective treatment option for NSCLC subtype

Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.

13 Sep 2012

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

The Neurodegeneration Consortium (NDC), a transformative multi-institutional initiative, will advance the study and treatment of Alzheimer's and other neurodegenerative diseases, thanks to an inaugural $25 million gift from the Robert A. and Renee E. Belfer Family Foundation to The University of Texas MD Anderson Cancer Center, Baylor College of Medicine and the Massachusetts Institute of Technology (MIT).

13 Sep 2012

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.

7 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

New findings establish connection between microRNAs and cellular metabolism

New findings establish a connection between microRNAs and cellular metabolism, suggesting that a drug designed to inhibit these tiny molecules -- once considered to be "junk" DNA -- would have a positive effect against obesity.

7 Sep 2012

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.

7 Sep 2012

Lymphoma News and Research

Further Reading

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Researchers identify subgroups of B cells in MYC-positive germinal centers

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

No link between low-level electromagnetic field exposure from mobile phones and health risks

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Objective response rate promising after crizotinib for NSCLC

Crizotinib may be effective treatment option for NSCLC subtype

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

Cell Therapeutics launches Pixuvri in the European Union

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Absence of Puma and Bim protein leads to autoimmune diseases

New findings establish connection between microRNAs and cellular metabolism

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News